{"transactions":[{"id":830823,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-23T20:05:11.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":60800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":60800,"derivative":{"exercise_price":6.81,"expiration_date":"2036-03-18","underlying":"Common Stock","underlying_shares":60800},"source":{"system":"sec-edgar","filing":"0001193125-26-119707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526119707/ownership.xml","form_type":"4"}},{"id":830822,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-23T20:05:11.000Z","date":"2026-03-20","kind":"sale","planned":false,"acquired":false,"shares":1915,"price":6.72,"value":12868.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Due to an administrative error, the Reporting Person filed a Form 4 on March 27, 2025 reporting beneficial ownership of 1,925 shares, when in fact the amount of securities beneficially owned was 1,915. The number of shares beneficially owned by the Reporting Person following the transaction reported herein has been updated accordingly."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-119707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526119707/ownership.xml","form_type":"4"}},{"id":1173322,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T21:27:32.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":50262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":50262,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":50262},"source":{"system":"sec-edgar","filing":"0000950170-25-053382","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053382/ownership.xml","form_type":"4"}},{"id":1189877,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-03-27T23:19:58.000Z","date":"2025-03-26","kind":"sale","planned":false,"acquired":false,"shares":907,"price":8.9693,"value":8135.1551,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.70 to $9.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2)."}],"balance_after":1925,"source":{"system":"sec-edgar","filing":"0000950170-25-046263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025046263/ownership.xml","form_type":"4"}},{"id":1249707,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-02-24T21:15:08.000Z","date":"2025-02-21","kind":"sale","planned":false,"acquired":false,"shares":96,"price":10.0758,"value":967.2768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":2832,"source":{"system":"sec-edgar","filing":"0000950170-25-025633","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025025633/ownership.xml","form_type":"4"}},{"id":1294526,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-27T21:15:17.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":4,"price":9.9402,"value":39.7608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":2928,"source":{"system":"sec-edgar","filing":"0000950170-25-009204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009204/ownership.xml","form_type":"4"}},{"id":1294525,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-27T21:15:17.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":32,"price":9.4538,"value":302.5216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025."}],"balance_after":2932,"source":{"system":"sec-edgar","filing":"0000950170-25-009204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025009204/ownership.xml","form_type":"4"}},{"id":1304349,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2025-01-13T21:15:06.000Z","date":"2025-01-10","kind":"sale","planned":false,"acquired":false,"shares":332,"price":0.4401,"value":146.1132,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.462. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":68174,"source":{"system":"sec-edgar","filing":"0000950170-25-004833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025004833/ownership.xml","form_type":"4"}},{"id":1357310,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-11-20T21:15:11.000Z","date":"2024-11-19","kind":"sale","planned":false,"acquired":false,"shares":554,"price":0.5485,"value":303.869,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":68506,"source":{"system":"sec-edgar","filing":"0000950170-24-129263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024129263/ownership.xml","form_type":"4"}},{"id":1374288,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-11-06T21:15:11.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":1655,"price":0.8649,"value":1431.4095,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":69060,"source":{"system":"sec-edgar","filing":"0000950170-24-122334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024122334/ownership.xml","form_type":"4"}},{"id":1382395,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:03.000Z","date":"2024-10-22","kind":"sale","planned":false,"acquired":false,"shares":486,"price":0.7678,"value":373.1508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.76 to $0.7709. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":70715,"source":{"system":"sec-edgar","filing":"0000950170-24-116646","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116646/ownership.xml","form_type":"4"}},{"id":1382394,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-10-23T20:15:03.000Z","date":"2024-10-21","kind":"sale","planned":false,"acquired":false,"shares":479,"price":0.779,"value":373.141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":71201,"source":{"system":"sec-edgar","filing":"0000950170-24-116646","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024116646/ownership.xml","form_type":"4"}},{"id":1390803,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-10-04T20:15:03.000Z","date":"2024-10-03","kind":"sale","planned":false,"acquired":false,"shares":301,"price":0.8148,"value":245.2548,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":71680,"source":{"system":"sec-edgar","filing":"0000950170-24-112911","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024112911/ownership.xml","form_type":"4"}},{"id":1427713,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-08-20T20:15:03.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":544,"price":0.7595,"value":413.168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":71981,"source":{"system":"sec-edgar","filing":"0000950170-24-099104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024099104/ownership.xml","form_type":"4"}},{"id":1438840,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-08-07T20:15:03.000Z","date":"2024-08-05","kind":"sale","planned":false,"acquired":false,"shares":1692,"price":0.7348,"value":1243.2816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":72525,"source":{"system":"sec-edgar","filing":"0000950170-24-092806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024092806/ownership.xml","form_type":"4"}},{"id":1449965,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-07-23T20:28:40.000Z","date":"2024-07-22","kind":"sale","planned":false,"acquired":false,"shares":481,"price":0.7392,"value":355.5552,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7330 to $0.7534. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":74217,"source":{"system":"sec-edgar","filing":"0000950170-24-085670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085670/ownership.xml","form_type":"4"}},{"id":1449964,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-07-23T20:28:40.000Z","date":"2024-07-19","kind":"sale","planned":false,"acquired":false,"shares":479,"price":0.7501,"value":359.2979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":74698,"source":{"system":"sec-edgar","filing":"0000950170-24-085670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024085670/ownership.xml","form_type":"4"}},{"id":1460124,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-07-03T20:12:53.000Z","date":"2024-07-02","kind":"sale","planned":false,"acquired":false,"shares":304,"price":0.72,"value":218.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":75177,"source":{"system":"sec-edgar","filing":"0000950170-24-081515","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024081515/ownership.xml","form_type":"4"}},{"id":1507235,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-05-21T20:35:19.000Z","date":"2024-05-17","kind":"sale","planned":false,"acquired":false,"shares":541,"price":0.7493,"value":405.3713,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":75481,"source":{"system":"sec-edgar","filing":"0000950170-24-062983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024062983/ownership.xml","form_type":"4"}},{"id":1524815,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-05-07T20:15:33.000Z","date":"2024-05-03","kind":"sale","planned":false,"acquired":false,"shares":1597,"price":0.796,"value":1271.212,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":76022,"source":{"system":"sec-edgar","filing":"0000950170-24-054510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024054510/ownership.xml","form_type":"4"}},{"id":1536903,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-04-23T20:15:24.000Z","date":"2024-04-22","kind":"sale","planned":false,"acquired":false,"shares":480,"price":0.75,"value":360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":77619,"source":{"system":"sec-edgar","filing":"0000950170-24-046906","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024046906/ownership.xml","form_type":"4"}},{"id":1536902,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-04-23T20:15:24.000Z","date":"2024-04-19","kind":"sale","planned":false,"acquired":false,"shares":473,"price":0.7506,"value":355.0338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":78099,"source":{"system":"sec-edgar","filing":"0000950170-24-046906","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024046906/ownership.xml","form_type":"4"}},{"id":1547825,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-04-04T20:15:12.000Z","date":"2024-04-02","kind":"sale","planned":false,"acquired":false,"shares":281,"price":0.772,"value":216.932,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":78572,"source":{"system":"sec-edgar","filing":"0000950170-24-041811","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024041811/ownership.xml","form_type":"4"}},{"id":1625492,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-22T21:15:33.000Z","date":"2024-02-20","kind":"sale","planned":false,"acquired":false,"shares":494,"price":0.6952,"value":343.4288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":78853,"source":{"system":"sec-edgar","filing":"0000950170-24-018780","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024018780/ownership.xml","form_type":"4"}},{"id":1651654,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-10T01:01:22.000Z","date":"2024-02-08","kind":"sale","planned":false,"acquired":false,"shares":11150,"price":0.6721,"value":7493.915,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.672 to $0.6721. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":79347,"source":{"system":"sec-edgar","filing":"0000950170-24-013491","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024013491/ownership.xml","form_type":"4"}},{"id":1656830,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-02-06T21:39:50.000Z","date":"2024-02-05","kind":"sale","planned":false,"acquired":false,"shares":5792,"price":0.67,"value":3880.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":90497,"source":{"system":"sec-edgar","filing":"0000950170-24-011770","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024011770/ownership.xml","form_type":"4"}},{"id":1670973,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-01-25T21:15:14.000Z","date":"2024-01-23","kind":"sale","planned":false,"acquired":false,"shares":901,"price":0.6708,"value":604.3908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6797. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":96289,"source":{"system":"sec-edgar","filing":"0000950170-24-007404","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024007404/ownership.xml","form_type":"4"}},{"id":1684272,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-01-08T21:15:26.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":310,"price":0.639,"value":198.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":97190,"source":{"system":"sec-edgar","filing":"0000950170-24-002934","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024002934/ownership.xml","form_type":"4"}},{"id":1696581,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-01-03T00:36:57.000Z","date":"2023-12-27","kind":"sale","planned":false,"acquired":false,"shares":28335,"price":0.7354,"value":20837.559,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7228 to $0.7452. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":97500,"source":{"system":"sec-edgar","filing":"0000950170-24-000428","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024000428/ownership.xml","form_type":"4"}},{"id":1732774,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-11-21T22:00:31.000Z","date":"2023-11-17","kind":"sale","planned":true,"acquired":false,"shares":403,"price":1.6311,"value":657.3333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":125835,"source":{"system":"sec-edgar","filing":"0001209191-23-056320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123056320/doc4.xml","form_type":"4"}},{"id":1756237,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-10-23T21:00:14.000Z","date":"2023-10-20","kind":"sale","planned":true,"acquired":false,"shares":357,"price":1.541,"value":550.137,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.53 to $1.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":126238,"source":{"system":"sec-edgar","filing":"0001209191-23-053347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123053347/doc4.xml","form_type":"4"}},{"id":1756236,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-10-23T21:00:14.000Z","date":"2023-10-19","kind":"sale","planned":true,"acquired":false,"shares":358,"price":1.58,"value":565.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":126595,"source":{"system":"sec-edgar","filing":"0001209191-23-053347","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123053347/doc4.xml","form_type":"4"}},{"id":1764354,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-10-05T21:00:10.000Z","date":"2023-10-03","kind":"sale","planned":true,"acquired":false,"shares":222,"price":1.9763,"value":438.7386,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.95 to $2.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":126953,"source":{"system":"sec-edgar","filing":"0001209191-23-052227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123052227/doc4.xml","form_type":"4"}},{"id":1800842,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-08-21T21:00:09.000Z","date":"2023-08-17","kind":"sale","planned":true,"acquired":false,"shares":1653,"price":2.4955,"value":4125.0615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.45 to $2.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":127175,"source":{"system":"sec-edgar","filing":"0001209191-23-046731","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123046731/doc4.xml","form_type":"4"}},{"id":1824881,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-07-21T21:00:11.000Z","date":"2023-07-20","kind":"sale","planned":true,"acquired":false,"shares":342,"price":3.3474,"value":1144.8108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":128828,"source":{"system":"sec-edgar","filing":"0001209191-23-043120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123043120/doc4.xml","form_type":"4"}},{"id":1824880,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-07-21T21:00:11.000Z","date":"2023-07-19","kind":"sale","planned":true,"acquired":false,"shares":342,"price":3.5615,"value":1218.033,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":129170,"source":{"system":"sec-edgar","filing":"0001209191-23-043120","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123043120/doc4.xml","form_type":"4"}},{"id":1857300,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-06-13T21:00:09.000Z","date":"2023-06-09","kind":"sale","planned":false,"acquired":false,"shares":5045,"price":5.6398,"value":28452.791,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":129512,"source":{"system":"sec-edgar","filing":"0001209191-23-036796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123036796/doc4.xml","form_type":"4"}},{"id":1915634,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-04-21T20:05:16.000Z","date":"2023-04-20","kind":"sale","planned":true,"acquired":false,"shares":349,"price":3.6255,"value":1265.2995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.  These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.62 to $3.64.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":134557,"source":{"system":"sec-edgar","filing":"0001209191-23-025116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123025116/doc4.xml","form_type":"4"}},{"id":1915633,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-04-21T20:05:16.000Z","date":"2023-04-19","kind":"sale","planned":true,"acquired":false,"shares":348,"price":3.7087,"value":1290.6276,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.  These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":134906,"source":{"system":"sec-edgar","filing":"0001209191-23-025116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123025116/doc4.xml","form_type":"4"}},{"id":2033129,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:00:26.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":113750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":251708,"derivative":{"exercise_price":6.65,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":113750},"source":{"system":"sec-edgar","filing":"0001209191-23-006989","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006989/doc4.xml","form_type":"4"}},{"id":2033128,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-02-03T22:00:26.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":61250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":135254,"source":{"system":"sec-edgar","filing":"0001209191-23-006989","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123006989/doc4.xml","form_type":"4"}},{"id":2048740,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-01-24T00:00:17.000Z","date":"2023-01-20","kind":"sale","acquired":false,"shares":338,"price":5.1438,"value":1738.6044,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":74004,"source":{"system":"sec-edgar","filing":"0001209191-23-004500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123004500/doc4.xml","form_type":"4"}},{"id":2048739,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-01-24T00:00:17.000Z","date":"2023-01-19","kind":"sale","acquired":false,"shares":1557,"price":5.0777,"value":7905.9789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":74342,"source":{"system":"sec-edgar","filing":"0001209191-23-004500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123004500/doc4.xml","form_type":"4"}},{"id":2118078,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-11-14T22:06:53.000Z","date":"2022-11-11","kind":"sale","acquired":false,"shares":18011,"price":8.176,"value":147257.936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.49. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":75899,"source":{"system":"sec-edgar","filing":"0000899243-22-035701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322035701/doc4.xml","form_type":"4"}},{"id":2118077,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-11-14T22:06:53.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":5989,"price":8.0021,"value":47924.5769,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.015. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":93910,"source":{"system":"sec-edgar","filing":"0000899243-22-035701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322035701/doc4.xml","form_type":"4"}},{"id":2131653,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-10-26T20:15:41.000Z","date":"2022-10-20","kind":"sale","acquired":false,"shares":345,"price":9.3607,"value":3229.4415,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":113233,"source":{"system":"sec-edgar","filing":"0000899243-22-034263","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034263/doc4a.xml","form_type":"4/A","original_submission_date":"2022-10-24"}},{"id":2133014,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-10-24T22:25:26.000Z","date":"2022-10-24","kind":"sale","acquired":false,"shares":2000,"price":8.1345,"value":16269.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.50. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":99899,"source":{"system":"sec-edgar","filing":"0000899243-22-034057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034057/doc4.xml","form_type":"4"}},{"id":2133013,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-10-24T22:25:26.000Z","date":"2022-10-21","kind":"sale","acquired":false,"shares":11334,"price":8.4524,"value":95799.5016,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.27 to $8.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":101899,"source":{"system":"sec-edgar","filing":"0000899243-22-034057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034057/doc4.xml","form_type":"4"}},{"id":2133012,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-10-24T22:25:26.000Z","date":"2022-10-19","kind":"sale","acquired":false,"shares":345,"price":9.3607,"value":3229.4415,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":113233,"source":{"system":"sec-edgar","filing":"0000899243-22-034057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322034057/doc4.xml","form_type":"4"}},{"id":2181866,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-08-17T21:57:08.000Z","date":"2022-08-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent restricted stock units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":113578,"source":{"system":"sec-edgar","filing":"0000899243-22-029043","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322029043/doc4.xml","form_type":"4"}},{"id":2212086,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-06T11:30:29.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":19500,"derivative":{"exercise_price":4.13,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0000899243-22-025236","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322025236/doc4.xml","form_type":"4"}},{"id":2212085,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-07-06T11:30:29.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,710 shares acquired under the AlloVir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022."}],"balance_after":93578,"source":{"system":"sec-edgar","filing":"0000899243-22-025236","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322025236/doc4.xml","form_type":"4"}},{"id":2291912,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-04-22T12:20:28.000Z","date":"2022-04-20","kind":"sale","acquired":false,"shares":276,"price":6.6843,"value":1844.8668,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.665 to $6.6976. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":80368,"source":{"system":"sec-edgar","filing":"0000899243-22-015390","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322015390/doc4.xml","form_type":"4"}},{"id":2308497,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-04T20:25:26.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":42558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":42558,"derivative":{"exercise_price":9.15,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":42558},"source":{"system":"sec-edgar","filing":"0000899243-22-013339","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322013339/doc4.xml","form_type":"4"}},{"id":2308496,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-04-04T20:25:26.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":17442,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":80644,"source":{"system":"sec-edgar","filing":"0000899243-22-013339","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322013339/doc4.xml","form_type":"4"}},{"id":2427842,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2022-01-24T21:15:20.000Z","date":"2022-01-20","kind":"sale","acquired":false,"shares":1563,"price":8.7526,"value":13680.3138,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.49 to $9.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":63202,"source":{"system":"sec-edgar","filing":"0000899243-22-003003","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322003003/doc4.xml","form_type":"4"}},{"id":2839618,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-24T00:43:08.000Z","date":"2021-02-22","kind":"sale","acquired":false,"shares":800,"price":43.1363,"value":34509.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.00 to $43.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":64765,"source":{"system":"sec-edgar","filing":"0001209191-21-013482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919121013482/doc4.xml","form_type":"4"}},{"id":2846423,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:44:07.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":541,"price":40.3931,"value":21852.6671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.06 to $40.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":65565,"source":{"system":"sec-edgar","filing":"0000899243-21-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007335/doc4.xml","form_type":"4"}},{"id":2846422,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T13:44:07.000Z","date":"2021-02-18","kind":"sale","acquired":false,"shares":200,"price":39.355,"value":7871.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.05 to $39.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":66106,"source":{"system":"sec-edgar","filing":"0000899243-21-007335","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007335/doc4.xml","form_type":"4"}},{"id":2850554,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:18:13.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":200,"price":41.68,"value":8336.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020."}],"balance_after":66306,"source":{"system":"sec-edgar","filing":"0000899243-21-007270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007270/doc4.xml","form_type":"4"}},{"id":2850553,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:18:13.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":1300,"price":41.1692,"value":53519.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.43 to $41.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":66506,"source":{"system":"sec-edgar","filing":"0000899243-21-007270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007270/doc4.xml","form_type":"4"}},{"id":2850552,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:18:13.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":220,"price":39.8613,"value":8769.486,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.22 to $39.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":67806,"source":{"system":"sec-edgar","filing":"0000899243-21-007270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007270/doc4.xml","form_type":"4"}},{"id":2850551,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:18:13.000Z","date":"2021-02-17","kind":"sale","acquired":false,"shares":600,"price":38.5633,"value":23137.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.16 to $39.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":68026,"source":{"system":"sec-edgar","filing":"0000899243-21-007270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007270/doc4.xml","form_type":"4"}},{"id":2850550,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:18:13.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":300,"price":42.6733,"value":12801.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.44 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":68626,"source":{"system":"sec-edgar","filing":"0000899243-21-007270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007270/doc4.xml","form_type":"4"}},{"id":2850549,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-02-19T02:18:13.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":2750,"price":41.8233,"value":115014.075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.35 to $42.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":68926,"source":{"system":"sec-edgar","filing":"0000899243-21-007270","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321007270/doc4.xml","form_type":"4"}},{"id":2900871,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-22T00:26:56.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":32500,"derivative":{"exercise_price":42.15,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000899243-21-002764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002764/doc4.xml","form_type":"4"}},{"id":2900870,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2021-01-22T00:26:56.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":71676,"source":{"system":"sec-edgar","filing":"0000899243-21-002764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321002764/doc4.xml","form_type":"4"}},{"id":3067698,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-06T01:54:58.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":6500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4361},"source":{"system":"sec-edgar","filing":"0000899243-20-021584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021584/doc4.xml","form_type":"4"}},{"id":3067697,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2020-08-06T01:54:58.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":4361,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."}],"balance_after":54176,"source":{"system":"sec-edgar","filing":"0000899243-20-021584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021584/doc4.xml","form_type":"4"}},{"id":3072592,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:34:17.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":43400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on July 29, 2021, with the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":43400,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":43400},"source":{"system":"sec-edgar","filing":"0000899243-20-020910","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020910/doc4.xml","form_type":"4"}},{"id":4358133,"issuer":{"id":77778,"kind":"organization","name":"KINETA, INC./DE","symbol":"KANT"},"owners":[{"id":56550,"kind":"person","name":"Hagen Brett R","position":1,"cik":"0001681782","reported_name":"Hagen Brett R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-04-05T16:37:52.000Z","date":"2017-04-03","kind":"grant","acquired":true,"shares":21100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These securities shall vest and become exercisable in a series of installments, with the first installment to become exercisable for 25% of the underlying common stock on March 8, 2018, and thereafter vesting and becoming exercisable in 12 quarterly installments as nearly equal as practicable (as determined by the Issuer in its reasonable discretion), until such stock option becomes fully exercisable on March 8, 2021, provided that the Reporting Person remains an employee of Issuer at all times during the applicable vesting period of such securities."}],"balance_after":21100,"derivative":{"exercise_price":7.56,"expiration_date":"2027-04-03","underlying":"Common Stock","underlying_shares":21100},"source":{"system":"sec-edgar","filing":"0001209191-17-025673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1445283/000120919117025673/doc4.xml","form_type":"4"}}]}